UTI confers broad and integrated protection of the intestine during sepsis. These findings suggest that IL-1β-mediated inflammatory signaling plays a key role in UTI-induced enteric neuroprotection and restoration of intestinal motility.

Drug screening identified the HIV protease inhibitor nelfinavir as a specific disruptor of the NIBAN2-FLII complex...Collectively, this study, for the first time, reveals that NIBAN2 maintains GSCs stemness by activating FLII-RREB1 axis and TLR3 signaling, thereby establishing a feed-forward signaling-transcription-metabolism axis. This finding provides a novel strategy and potential targets for precise therapeutic intervention against glioma stemness.

P3, N=348, Completed, Tata Memorial Hospital | Active, not recruiting --> Completed

In some cell lines, the fiber modification F5RGD10(2C) or verapamil treatment further improves actual spread efficiency. Nelfinavir inhibits spread and plaque formation of oncolytic adenoviruses with the 19KSS-iLQ125Ter modifications, irrespective of adenovirus death protein (ADP) expression...We identified an insertion site downstream of the L3-23K region that supports relatively high hPH20 activity while preserving the enhanced oncolytic potency of the virus. Combining 19KSS-iLQ125Ter with hPH20 expression may potentially improve therapeutic benefit in glioma.

Pyroptosis is a newly defined form of programmed cell death characterized by plasma membrane perforation, release of cellular contents, and a robust inflammatory response, thereby sensitizing tumors to existing anticancer therapies. Furthermore, the combination of SAQ with sorafenib, a first-line therapeutic agent for HCC, exhibited synergistic antitumor activity both in vitro and in the nude mouse model. These findings not only identify SAQ as a novel pyroptosis-inducer, but also clarify the critical role of the OTUD5-JAK1-GSDME axis in resisting pyroptosis, which may further provide experimental evidence and potential new strategies for treating HCC.

UTI+SS for SAP is effective in clinical efficacy enhancement and serum inflammation suppression.

P3, N=348, Active, not recruiting, Tata Memorial Hospital | Trial completion date: Jan 2026 --> Apr 2026

P2, N=60, Not yet recruiting, The First Affiliated Hospital, Sun Yat-sen University; The First affiliated hospital, sun yat-sen university

P3, N=348, Active, not recruiting, Tata Memorial Hospital | Trial completion date: Sep 2025 --> Jan 2026

Besides, combination treatment with GLS4 and ritonavir elevates the frequencies of both peripheral blood IFNγ + NK cells and liver-resident IFNγ + CD8+ T cells in the pAAV/HBV1.2 hydrodynamic injection (HDI) model. Furthermore, GLS4 partially restores innate and adaptive immunity in vivo. This signifies a potentially effective strategy for achieving a functional cure for HBV infection.

P1, N=19, Completed, Cytonics Corporation | Not yet recruiting --> Completed | Trial completion date: Dec 2024 --> Oct 2025

P2, N=38, Recruiting, Medical University of South Carolina | Not yet recruiting --> Recruiting | N=20 --> 38 | Trial completion date: Dec 2027 --> Jun 2029 | Trial primary completion date: Dec 2026 --> Jun 2028